Back
Empresa Distribuidora y Comercializadora Norte SA 10K Form
Sell
44
EDN
Empresa Distribuidora y Comercializadora Norte SA
Last Price:
$42.23
Seasonality Move:
-2.33%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive EDN News And Ratings
See the #1 stock for the next 7 days that we like better than EDN
EDN Financial Statistics
Sales & Book Value
Annual Sales: | $2.7B |
---|---|
Cash Flow: | $-45.6M |
Price / Cash Flow: | 0 |
Annual Sales: | $26.49 |
Price / Book: | 1.6 |
Profitability
EPS (TTM): | -1.21760 |
---|---|
Net Income (TTM): | $-53.3M |
Gross Margin: | $105.7M |
Return on Equity: | -6.05% |
Return on Assets: | -1.83% |
Empresa Distribuidora y Comercializadora Norte SA Earnings Forecast
Key Empresa Distribuidora y Comercializadora Norte SA Financial Ratios
-
The Gross Profit Margin over the past 21 years for EDN is 3.95%.
-
The Selling, General & Administrative Expenses for EDN have been equal to 16.24% of Gross Profit Margin.
-
The Research & Development expenses have been 0.00% of Revenue.
-
The Interest Expense is 659.23% of Operating Income.
-
The Net Earning history of EDN is 6.90% of Total Revenues.
-
Per Share Earnings over the last 22 years have been positive in 8 years.
Empresa Distribuidora y Comercializadora Norte SA Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Electric Utilities |
Sector: | Utilities |
Current Symbol: | EDN |
CUSIP: | 29244A |
Website: | edenor.com |
Debt
Debt-to-Equity Ratio: | 0.29 |
---|---|
Current Ratio: | 0.82 |
Quick Ratio: | 0.68 |
Price-to-Earnings
Trailing P/E Ratio: | 10.03 |
---|---|
Forward P/E Ratio: | 68.23 |
EDN Technical Analysis vs Fundamental Analysis
Sell
44
Empresa Distribuidora y Comercializadora Norte SA (EDN)
is a Sell
Is Empresa Distribuidora y Comercializadora Norte SA a Buy or a Sell?
-
Empresa Distribuidora y Comercializadora Norte SA stock is rated a SellThe current Empresa Distribuidora y Comercializadora Norte SA [EDN] share price is $42.27. The Score for EDN is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.